great quarter almost measur strateg question havent gone away
remain neutral rate share also acknowledg outstand
print driven humira upsid inaugur skyrizi print surpris us even
recent survey indic drug launch would someth special
nit quarter exist hcv franchis continu soften orilissa
remain disappoint think strength elsewher offset issu
portend strong finish said remain skeptic
strateg merit allergan combin especi context manag
posit combin busi well posit even
humira ultim ww eros curv remain much wild card remain
stellar beat non-gaap ep beat consensu pjc
total revenu beat consensu pjc driven primarili
stronger-than-predict perform humira vs consensu
pjc newli approv skyrizi vs pjc beyond immunolog
asset franchis gener miss includ miss hcv
franchis driven lower treatment volum select ex-u market miss
orilissa quarter
guidanc rais bode well non-gaap ep guidanc rais
midpoint previous consensu
revenu growth guidanc rais oper basi
increas guidanc primarili driven increas global hem/onc revenu
previous consensu skyrizi revenu expect
ski limit skyrizi rais estim listen close
recent survey feedback derm indic skyrizi would captur biologic-tr
pso market share within first month launch today impress show
increas skyrizi revenu guidanc rais ww
estim respect
still sold allergan deal though financi strategi
allergan acquisit continu highlight manag remain skeptic
long-term strateg fit combin on-going humira pressur ex-u
biosimilar competit shift us market altern moa treatment continu
give us paus chang price target reiter neutral rate
commerci regulatori clinic ip risk associ market pipelin product
fulli integr biopharmaceut compani
ep discount back
year
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
strong skyrizi perform manag guidanc revis
make chang model
first rais ww skyrizi revenu estim
respect previous respect
also think strong launch bode well upadacitinib launch trajectori
increas ww upa revenu estim respect
previous respect though chang upa
estim also rais near-term us ex-u humira
imbruvica revenu estim match new guidanc partial off-set
lower hcv revenu near long-term moder orilissa revenu estim
manag cut orilissa revenu guidanc half model
adjust product tweak expens net impact
total revenu estim increas respect
ep estim increas ahead new guidanc rang
ep estim increas ahead new guidanc rang
minim impact ep out-year chang target
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
dollar except per share data
row revenu
elotuzumab revenu
total ww elotuzumab revenu
row profit shaqe
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
